 |
|
|
|
|
 |
 |
Translational Cancer Therapeutics Center of Economic Excellence
University collaborators: Medical University of South Carolina (fiscal agent) University of South Carolina (collaborative partner)
About the CoEE: The Translational Cancer Therapeutics CoEE builds on existing strengths in pharmacology at USC and MUSC and expands opportunities for increased interdisciplinary research to enhance scientific research in the biology common to cancer. As research builds in the discovery and development of cancer drugs, the state economy will be strengthened by biotechnology companies with pharmaceutical interests. Collaborative work with Novelos Pharmaceuticals has led to unrestricted research funding totaling more than $750,000 since 2005 to study lung and ovarian cancer. A portion of this support funded a breast cancer clinical trial at MUSC, which in turn was instrumental in the pursuit and acquisition of the NCI Cancer Center designation for the Hollings Cancer Center. This CoEE was also instrumental in MUSC obtaining the NIH $20 million Clinical Translational Science Award, which was presented in July 2009. To date, federal funding for this CoEE totals more than $5 million. In 2007, this CoEE and CoEE Chair Dr. Kenneth Tew hosted the Hollings Cancer Center Spring Symposium on Cancer Drug Discovery/Drug Development at Kiawah Island. This event drew numerous pharmaceutical companies to the state and was an excellent opportunity for South Carolina drug researchers to showcase the state’s prospects for drug discovery and development. Funding level: CoEE endowed chair:
|
